Learn about the effects of sickle cell anemia during pregnancy, its health risks, management tips, and ways to ensure a safer pregnancy journey with proper care.
Sickle cell anemia (SCA) is a genetic blood disorder in which the red blood cells, which are usually round and elastic, become inflexible and crescent- or sickle-shaped. These deformed cells can obstruct blood flow, causing pain, damage to organs, and increased susceptibility to infections.
Sickle cell anemia and pregnancy is high-risk because the mother and the fetus are more likely to develop complications. Nevertheless, with close medical supervision and attention, most women with SCA can experience successful pregnancies.
Relationship between Sickle Cell Anemia and Pregnancy
Sickle cell anemia and Pregnancy are closely related since pregnancy increases the physical demand on the body, which can aggravate the complications of SCA. Conversely, Sickle cell anemia influences the success of a pregnancy with the way it affects blood circulation, oxygen supply, and organ function.
This compatibility indicates:
Elevated Physical Requirement during Pregnancy
Pregnancy elevates blood volume, heart rate, and oxygen requirement.
Red blood cells are already defective in carrying oxygen in sickle cell anemia.
This worsens anemia and causes more frequent sickle cell crises (painful crises due obstructed blood vessels).
Vascular and Placental Complications
Sickle cells are adhesive and tend to obstruct blood vessels.
During pregnancy, this can impair placental blood flow, causing:
Poor oxygen and nutrient supply to the fetus
Risk of miscarriage, stillbirth, or intrauterine growth restriction (IUGR)
Decreased Immune Function and Infection
Sickle Cell Anemia and Pregnancy both compromise the immune system.
SCA women, who are pregnant, are at higher risk for infections (e.g., UTIs, pneumonia) that can initiate crises or cause preterm labor.
Complications Such as Preeclampsia and Blood Clots
SCA raises the risk of hypertension and preeclampsia.
The disease also raises the risks of clotting, and pregnancy already thins the blood, making it more susceptible to clots — doubling the threat.
Genetic Link
SCA is hereditary. An expectant mother with SCA can transmit the gene to the child.
If both parents have the sickle cell trait, there's a:
25% chance the child will have sickle cell anemia
50% chance the child will have the trait
25% chance the child won't be affected
Sickle cell disease and pregnancy management
Sickle Cell Disease (SCD) and Pregnancy Management is best managed using a multidisciplinary team because of the added risks to both the fetus and mother. Below is an organized outline:
Overview of SCD in Pregnancy
Sickle Cell Disease is a hemoglobin genetic disorder that results in the sickling, vaso-occlusion, hemolytic anemia, and organ damage of red blood cells.
Pregnancy augments complications because of physiologic stress, hypercoagulability, and immune suppression.
Pregnancy risks with sickle cell anemia
Pregnancy Complications in Sickle Cell Anemia are much greater than in the general population because of the chronic disease complications and higher physiological demands of pregnancy. This is a structured summary:
Maternal Pregnancy Complications in Sickle Cell Disease:
Vaso-occlusive crises (VOCs)
Hypoxia-, dehydration-, infection-, or stress-induced painful episodes; more common in pregnancy.
Acute Chest Syndrome (ACS)
Life-threatening condition with chest pain, fever, and hypoxia; usually precipitated by infection or embolism.
Severe Anemia
Secondary to chronic hemolysis; can necessitate recurrent transfusions.
Infections
Functional asplenia leads to increased risk of UTIs, pneumonia, and sepsis.
Preeclampsia/Eclampsia
Increased risk of hypertensive disorders of pregnancy.
Thromboembolism
Increased risk secondary to hypercoagulability of pregnancy and SCD.
Pulmonary Hypertension
Can worsen during pregnancy and contribute to increased maternal mortality.
Stroke
Increased risk secondary to vaso-occlusion and anemia.
Maternal Mortality
2–10 times that of the general population in some areas.
Fetal Risks in Pregnancy with Sickle Cell Anemia:
Intrauterine Growth Restriction (IUGR)
Placental insufficiency caused by sickling in placental vessels.
Preterm Labor and Birth
Frequently caused by maternal disease or iatrogenic induction.
Low Birth Weight
Frequent in SCD pregnancies.
Miscarriage
Increased risk, especially in poorly controlled disease.
Stillbirth
Increased because of fetal hypoxia and placental infarctions.
Neonatal Death
Risk increased particularly in low-resource settings.
Sickle cell anemia and pregnancy guidelines
Below are the official pregnancy management guidelines for women with Sickle Cell Anemia (SCA), according to prominent international recommendations like those of the Royal College of Obstetricians and Gynaecologists (RCOG), American College of Obstetricians and Gynaecologists (ACOG), and WHO:
Sickle Cell Anemia and Pregnancy Guidelines:
Preconception Care
Genetic counselling for the patient and her partner to determine risk of fetal sickle cell disease.
Screen the partner for other hemoglobinopathies (HbAS, HbC, etc.).
Check for baseline complications: renal, cardiac, liver function, pulmonary hypertension.
Initiate high-dose folic acid (4–5 mg/day).
Update vaccination status: pneumococcal, meningococcal, H. influenzae, hepatitis B, influenza.
Antenatal Care
Multidisciplinary team management: obstetrician, hematologist, anesthetist, pediatrician.
Increase frequency of antenatal visits (monthly to bimonthly in third trimester).
Watch for:
Hemoglobin levels
Urinary tract infections
Fetal growth (serial ultrasounds at 4-weekly intervals from 24 weeks)
Educate on prevention of triggers (dehydration, cold, infection, overexertion).
Administer low-dose aspirin (75–150 mg/day) from 12 weeks to lower preeclampsia risk.
Prescribe prophylactic blood transfusions in:
Severe complications in the past
Recurrent VOCs
Previous bad pregnancy outcome
Use iron supplements only if iron deficiency is established (not routine).
Pain management: paracetamol first line; opioids if necessary; NSAIDs avoided in late pregnancy.
Infection prevention: treat promptly, urine culture every trimester.
Intrapartum Care
Delivery planned at a tertiary care facility.
Vaginal delivery to be preferred except when obstetric reasons for cesarean.
Ensure:
Proper hydration
Oxygen therapy if hypoxic
Pain relief by epidural analgesia
Continuous fetal monitoring
Avoid prolonged labor, hypoxia, and acidosis.
In high-risk cases, consider prophylactic blood transfusion prior to delivery.
Postpartum Care
Resume hydration and oxygen support as required.
Closely monitor for:
VOCs
Infections
Postpartum hemorrhage
Thromboembolic events
Institute thromboprophylaxis with LMWH for 7 days after delivery (longer in the case of cesarean or immobility).
Encourage early ambulation.
Breastfeeding should be encouraged (safe in most pain medications and folic acid).
Discuss contraception:
Avoid combined estrogen contraceptives in high-risk women
Use progestin-only pills, IUDs, or implants
Special Considerations
Avoid hydroxyurea use in pregnancy and lactation because of teratogenic risk.
Avoid NSAIDs in 3rd trimester because of risk of premature closure of the ductus arteriosus.
Be vigilant for acute chest syndrome, preeclampsia, or fetal compromise.
Sickle cell disease pregnancy outcomes
Pregnancy in women with Sickle Cell Disease (SCD), especially homozygous HbSS, is high-risk because it has much higher levels of maternal, fetal, and neonatal complications in comparison to the general population.
Adverse Maternal Outcomes:
Vaso-occlusive crises (VOCs)
Increased due to elevated metabolic demand and changes in blood volume.
Acute chest syndrome (ACS)
One of the most common causes of maternal death in SCD pregnancies.
Severe anemia
Prevalent due to hemolysis; may need to be transfused.
Preeclampsia/Eclampsia
Incidence much higher than in non-SCD pregnancies.
Infections
Increased risk of urinary tract infections, pneumonia, and sepsis.
Venous thromboembolism (VTE)
Pregnancy and SCD are pro-thrombotic conditions.
Pulmonary hypertension, stroke, or heart failure
May exacerbate during pregnancy, with a rise in maternal mortality.
Maternal mortality
Up to 10-fold higher in low-resource environments.
Poor Fetal and Neonatal Outcomes:
Intrauterine Growth Restriction (IUGR)
Attributed to placental infarctions due to vaso-occlusion.
Low birth weight (<2.5 kg)
Observed in up to 40–60% of SCD pregnancies.
Preterm birth (<37 weeks)
Usually because of maternal complications or medical indication for delivery.
Stillbirth
Placental insufficiency and maternal disease raise the risk.
Spontaneous abortion
Increased rate of first-trimester miscarriage.
Perinatal and neonatal death
Increased, especially in those with poor neonatal care.
Apgar score <7 at 5 minutes
With neonatal complications.
Managing sickle cell anemia during pregnancy
Sickle cell anemia (SCA) management during pregnancy is a multidisciplinary, proactive, and individualized process aimed at optimizing maternal and fetal outcomes. The aim is prevention of complications, observation of maternal and fetal health, and safe delivery.
Preconception and Early Pregnancy Care
Preconception Counselling
Genetic testing and partner screening to determine fetal risk.
Prompt antibiotics, particularly for UTI or resp infection.
Preeclampsia
Treat per obstetric protocol; delivery in severe cases or at or near term.
Intrapartum Care
Delivery Planning
At 37–39 weeks if stable. Earlier with complications.
Preferred Mode
Vaginal delivery unless obstetric need for cesarean.
Monitoring
Continuous fetal heart rate monitoring.
Pain Relief
Epidural is safe and preferred.
Hydration and Oxygen
Continue IV fluids and oxygenation through labor.
Postpartum Care
Watch for VOCs or ACS
Particularly in the first 72 hours postpartum.
Thromboprophylaxis
LMWH for 7 days after vaginal, 6 weeks after cesarean or high-risk.
Encourage Breastfeeding
Safe even on opioids or most medications.
Early Ambulation
To decrease risk of thrombosis.
Contraception Counselling
Progestin-only pills, implants, or IUDs. Avoid estrogen pills if risk of thrombosis.
Blood Cross-match
Have blood available in case of transfusion risk.
Sickle cell anemia and fetal health
Pregnancy in a woman with sickle cell anemia (SCA) is risky to the health of the fetus because of maternal complications such as anemia, vaso-occlusion, and placental insufficiency. These impair oxygen and nutrient delivery to the fetus, which influences growth and survival.
How Sickle Cell Anemia Affects the Fetus?
Placental vaso-occlusion
Decreased blood flow leads to intrauterine growth restriction (IUGR).
Chronic maternal anemia
Triggers fetal hypoxia, impaired growth, and enhanced distress.
Increased maternal infections
May cause preterm labor or fetal loss.
Sickling in placental vessels
Results in placental infarction, diminishing nutrient exchange.
Acute maternal complications (e.g. VOCs, ACS)
Can lead to precipitating fetal hypoxia, stillbirth, or preterm delivery.
Sickle cell anemia and pregnancy treatment options
Management of sickle cell anemia and pregnancy is aimed at preventing and treating complications, enhancing maternal health, and promoting optimal fetal outcomes. Management is supportive, preventive, and tailored, depending on maternal status and pregnancy duration.
Supportive Therapy
Blood Transfusions
Drug Management
Prevention and Management of Infections
Fetal Monitoring and Surveillance
Intrapartum and Delivery Management
Postpartum Care
Sickle cell anemia and maternal health in pregnancy
Pregnancy in patients with major Sickle Cell Anemia (SCA) is complicated by the underlying chronic hemolytic anemia, vascular impairment, and common vaso-occlusive events. These maternal morbidities are magnified by the physiologic changes of pregnancy, elevating morbidity and mortality.
Effect of Pregnancy on Maternal Health with Sickle Cell Anemia
Increased cardiac output and blood volume
Worsens initial anemia
Immunosuppression
Increases susceptibility to infections
Hypercoagulability
Augments thrombotic risks (DVT, PE)
Decreased oxygen carrying capacity
Augments risk of tissue hypoxia and VOCs
Hormonal changes and placental requirements
May initiate crises and complications
Sickle cell anemia and pregnancy care plan
Preconception
Genetic counselling (partner screening)
Discontinue hydroxyurea
Initiate folic acid 4–5 mg/d
Update immunizations
Antenatal Care
Multidisciplinary team (OB, hematology, anesthesiology)
Monthly visits → biweekly in 3rd trimester
Serial ultrasounds (q4 weeks from 24 weeks)
Follow CBC, LFTs, RFTs, urine culture
Low-dose aspirin (75–150 mg/day from 12 weeks)
Transfusions if Hb <7 g/dL or frequent VOCs
Infection screen and treatment
Pain: Paracetamol ± opioids (avoid NSAIDs late pregnancy)
Intrapartum Care
Delivery planned at 37–39 weeks in tertiary center
IV fluids, oxygen, pain relief (epidural ideal)
Continuous fetal monitoring
Cross-matched blood preoperatively
Postpartum Care
Thromboprophylaxis with LMWH (7–42 days)
Watch for VOCs, infection
Breastfeeding support
Family planning: IUD or progestin-only contraceptive
Sickle cell anemia and labor and delivery
Women with sickle cell anemia (SCA) are at risk of increased threats to both themselves and their infants during labor and delivery from the effects of anemia, vaso-occlusion, and organ dysfunction. Careful planning and support are necessary to provide safe outcomes for both mother and infant.
Most Important Objectives During Labor and Delivery
Avoid sickling crises
Provide oxygenation and hydration
Provide pain control
Monitor fetal distress
Prepare for emergencies
Sickle cell anemia and breastfeeding
Breastfeeding is not only safe but also highly recommended for sickle cell anemia (SCA) patients. The majority of drugs employed in SCA treatment are safely used during breastfeeding, and advantages should supersede any risk when adequately supervised.
Can Women with Sickle Cell Anemia Breastfeed?
Yes. SCD in itself is not a contraindication for breastfeeding. Breastfeeding provides:
Immune and nutritional advantages for the infant
Emotional attachment
Natural contraception assistance in early postpartum (lactational amenorrhea)
Sickle cell anemia genetic counselling during pregnancy
Genetic counselling is an essential aspect of prenatal management in couples in which one or both the partners are HbAS bearers or HbSS anemic patients. It is useful in informing parents about the risk of inheritance, availability of tests, and reproductive decisions.
Objectives of Genetic Counselling during Pregnancy
Evaluate fetal risk of inheriting SCD
Educate the couple regarding patterns of inheritance and prognosis
Explain testing possibilities: prenatal and preimplantation genetic diagnosis (PGD)
Support informed decision-making (emotional, ethical, and medical considerations).
Why Choose GetWellGo for Sickle Cell Anemia and Pregnancy?
GetWellGo is regarded as a leading supplier of healthcare services. We help our foreign clients choose the best treatment locations that suit their needs both financially and medically.
We offer:
Complete transparency
Fair costs.
24 hour availability.
Medical E-visas
Online consultation from recognized Indian experts.
Assistance in selecting India's top hospitals for sickle cell anemia and pregnancy.
Expert doctor with a strong track record of success
Assistance during and after the course of treatment.
Language Support
Travel and Accommodation Services
Case manager assigned to every patient to provide seamless support in and out of the hospital like appointment booking
Local SIM Cards
Currency Exchange
Arranging Patient’s local food
Case Study of Courage: Pregnancy with Sickle Cell Anemia Managed with GetWellGo
Patient Name: Achieng’ Mary Odhiambo.
Age: 28 years old
Gender: Female
Country of Origin: Kenya
Name of the doctor: Dr. Vikas Dua and Multidisciplinary Team
Name of the Hospital: Fortis Memorial Research Institute, Gurgaon
Treatment: Pregnancy Care and Sickle Cell anemia treatment
This is what happened to one of the 28 years Kenyan women known as Achieng’ Mary Odhiambo. who was already living with sickle cell anemia and had to deal with her health in addition to being a pregnant woman. The condition was quite dangerous to not only her but also to her unborn baby. She had frequent pain crises, fatigue and reduced immunity, and her pregnancy was considered to be at high-risk, which is why her family sought the high-tech solutions in other countries.
The family initially discovered the platform GetWellGo through thorough research and referral and was guided towards special care in India. GetWellGo international patient services arranged the whole process of medical traveling, including picking up and accommodating at the airport and seeing Fortis Memorial Research Institute as one of the top hospitals in Gurgaon, which had to be given priority.
In Fortis, Odhiambo was admitted and was taken care of by Dr. Vikas Dua, one of the senior pediatric hematologists, a multidisciplinary team comprising obstetricians, hematologists, and maternal-fetal medicine specialists. The team also collaborated to develop a tailor-made treatment plan which considered both her management of sickle cell and pregnancy.
Through close observation, high-end drugs, and supportive blood transfusion where needed, the state of Odhiambo was maintained during the course of pregnancy. Regular check-ups, nutritional advice, and pain management therapies were administered to her to reduce sickle cell crises. The tight cooperation between the hematology and obstetrics kept both the mother and the baby safe at all times.
Odhiambo had to undergo months of intensive care and follow-ups but at the end of it all, she was able to give birth to a healthy baby. She was still being followed up on recovery after delivery, and the emphasis was on reducing the complications and assisting her in long term health care.
In her speech Achieng’ Mary Odhiambo shared her gratitude:
The idea of carrying a pregnancy with a sickle cell anemia was intimidating, yet with the help of Dr. Vikas Dua, his staff, and the support of GetWellGo all the time, I felt safe throughout the process. The attention and synchronization I received made all the difference. I am a blessed woman today with a healthy child and the strength to go on with my life with a fresh hope.
We congratulate Odhiambo on her bravery and strength and wish her whole heartedly for her health and happiness and be well with her baby.
GetWellGo offers expert neuroblastoma pediatric oncology care in India with advanced treatments like chemotherapy, surgery, and immunotherapy, ensuring hope and specialized support for children.
Wilms tumor treatment in India offers world-class pediatric cancer care with expert oncologists, advanced therapies, and affordable options tailored for international patients.
India is a top choice for esophagectomy, blending advanced care with affordability. GetWellGo helps international patients access trusted hospitals & surgeons.
GetWellGo supports international patients with ependymoma care, offering guidance on diagnosis, treatment choices, and access to trusted global healthcare.
Learn about ovarian germ cell tumors, including diagnosis, treatment options, and expert care in India. Understand symptoms, therapies, and support for better patient outcomes.
Advanced gastric cancer treatment in India offers international patients expert oncologists, modern therapies, and affordable care with high success rates and personalized treatment plans.
India provides world-class care for embryonal tumor treatment with advanced therapies, expert oncologists, and affordable costs, making it a trusted choice for international patients.
GetWellGo connects global patients to India’s top doctors for Primary CNS Lymphoma care—advanced treatments, trusted expertise & affordable healthcare.
Advanced lymphedema treatment in India offers patients modern therapies, expert care, and affordable options to manage swelling and improve life quality with long-term results.
Bone marrow biopsy in India offers accurate diagnosis for blood disorders and cancers, with expert hematologists, advanced labs, and affordable care in top hospitals.